Kang Seok-Gu, Cheong Jae-Ho, Huh Yong Min, Kim Eui Hyun, Kim Sun Ho, Chang Jong Hee
Department of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea,
Arch Pharm Res. 2015 Mar;38(3):402-7. doi: 10.1007/s12272-015-0564-0. Epub 2015 Jan 29.
A decade ago, cancer stem cells (CSCs) were introduced as target cells for an innovative cancer treatment. Particularly, there have been a lot of biological researches on glioblastoma (GBM) CSCs. However, as there is a comprehensive change in the concept of CSCs, it is required to review how the different CSCs for patients can be clinically used, or clinical credentialing, and summarize the possibilities of clinical credentialing. In this regard, this review aims to introduce the tumorsphere obtained from GBM specimen and summarize the clinical dilemma and clinically applicable areas.
十年前，癌症干细胞（CSCs）作为一种创新癌症治疗的靶细胞被引入。特别是，针对胶质母细胞瘤（GBM）的癌症干细胞已经开展了大量生物学研究。然而，由于癌症干细胞的概念发生了全面变化，有必要审视针对不同患者的癌症干细胞如何在临床上应用，即临床鉴定，并总结临床鉴定的可能性。在这方面，本综述旨在介绍从GBM标本中获得的肿瘤球，并总结临床困境和临床适用领域。
